Conflict over NIH funding poses tough choices for biopharma
Cuts to NIH funding foreshadow bigger challenges for biomedical research, tough trade-offs for biotech and pharma companies
The Trump administration on Friday announced immediate cuts to NIH overhead payments for academic institutions, only for a federal judge to partially block the policy Monday in response to lawsuits from 22 states. The abrupt reversal underscores the uncertainty facing the life sciences as President Donald Trump and his adviser Elon Musk pursue aggressive efforts to slash research funding and curb the influence of major research institutions.
White House plans to restructure and reduce spending on academic biomedical research threaten short- and long-term harms to the biopharmaceutical industry. These include disrupting ongoing collaborations, as well as slowing the pace and narrowing the scope of the basic scientific advances that underpin biomedical progress. ...